Idalopirdine

A serotonin receptor antagonist

Idalopirdine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Idalopirdine is a pharmaceutical drug that was investigated for its potential use in the treatment of Alzheimer's disease. It acts as a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor.

Pharmacology

Idalopirdine is known to function primarily as a 5-HT6 receptor antagonist. The 5-HT6 receptor is predominantly located in the central nervous system, particularly in regions of the brain associated with cognition and memory, such as the cortex and the hippocampus. By blocking this receptor, idalopirdine was hypothesized to enhance the release of neurotransmitters like acetylcholine, dopamine, and glutamate, which are crucial for cognitive processes.

Development and Clinical Trials

Idalopirdine was developed by Lundbeck, a pharmaceutical company, and was initially considered a promising candidate for the treatment of Alzheimer's disease. The drug underwent several clinical trials to assess its efficacy and safety.

Phase II Trials

In early trials, idalopirdine showed some potential in improving cognitive function in patients with mild to moderate Alzheimer's disease. These trials suggested that the drug could enhance the effects of existing acetylcholinesterase inhibitors, which are commonly used to treat symptoms of Alzheimer's.

Phase III Trials

Despite the initial promise, subsequent Phase III clinical trials did not demonstrate significant improvements in cognitive outcomes compared to placebo. The trials involved large cohorts of patients and were designed to rigorously test the efficacy of idalopirdine as an adjunct therapy to standard Alzheimer's treatments. Unfortunately, the results did not support the continued development of the drug for this indication.

Mechanism of Action

The mechanism by which idalopirdine was expected to work involves the modulation of neurotransmitter systems in the brain. By antagonizing the 5-HT6 receptor, idalopirdine was thought to increase the levels of neurotransmitters that are typically deficient in Alzheimer's disease. This receptor blockade was hypothesized to lead to enhanced cholinergic and glutamatergic neurotransmission, potentially improving cognitive function.

Discontinuation

Due to the lack of efficacy demonstrated in the Phase III trials, the development of idalopirdine for Alzheimer's disease was discontinued. The failure of idalopirdine highlights the challenges in developing effective treatments for neurodegenerative diseases and the complexity of Alzheimer's pathology.

Related pages

• Alzheimer's disease
• 5-HT6 receptor
• Serotonin receptor
• Neurotransmitter